摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 137211-86-0

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
137211-86-0
化学式
C6H15N*C83H84Cl3N10O28P3
mdl
——
分子量
1970.1
InChiKey
XIARKAQIVJICOY-MFGOKFDPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    14.13
  • 重原子数:
    134.0
  • 可旋转键数:
    35.0
  • 环数:
    15.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    457.42
  • 氢给体数:
    4.0
  • 氢受体数:
    36.0

反应信息

  • 作为反应物:
    参考文献:
    名称:
    New regiospecific synthesis of branched tetra-, nona- & deca-RNA modelling the lariat formed in RNA splicing reactions
    摘要:
    Convergent syntheses of branched tetraribonucleotide 39, nonaribonucleotide 40 and decaribonucleotide 41, modelling the lariat of pre-mRNA processing reaction, are reported. The first key step in the present strategy involves the condensation of the phosphodiester blocks 1, 5 or 15 with the 3',5'-dihydroxy-6-N-benzoyl-2'-O-pixyl(9-phenylxanthen-9-yl)adenosine 29 to give 30a (65%), 31a (63%) or 32a (70%). Chemospecific phosphorylation at 3'-OH of these intermediates afforded the intermediates 30b (92%), 31b (83%) or 32b (80%) which were treated with mild acid to achieve a regiospecific removal of the 2'-O-pixyl group to give compounds 30c (74%), 31c (86%) or 32c (85%). The second key step involved the introduction of biscyanoethylphosphotriester moiety to the 2'-OH of the branch-point adenosine in 30c, 31c or 32c in one single step using (biscyanoethoxy)-(diisopropylamino)phosphine to give the crucial branch-point building blocks 30d (46%), 31d (64%) or 32d (62%) with two dissimilar vicinal phosphates at 2'- and 3'- of the branch-point. These blocks were then converted to the fully protected intermediates 33a (59%) [30d+28 --> 33a], 34a (69%) [31d+19 --> 34a] and 35a (56%) [32d+19 --> 35a], and were subsequently treated with a bulky tertiary amine to give the branch-point 2'-cyanoethylphosphodiester blocks 33b (64%), 34b (67%) and 35b (68%). These were then condensed in the usual way with the appropriate 5'-hydroxy block (27 or 25) to give the fully protected branched oligomers 36 (69%) [33b+27 --> 36], 37 (67%) [34b+25 --> 37] and 38 (63%) [35b+25 --> 38]. These oligomers were then deprotected in the usual manner to give the final branched oligoribonucleotides 39, 40 and 41 in 62%, 21% and 21% yields respectively. Detailed 500 MHz H-1-NMR and 202.4 MHz P-31-NMR studies on 39, 40 and 41 have unequivocally established their purities. Detailed spectroscopic studies such as COSY, HOHAHA & NOESY have also clearly established the structural integrity of the synthetic target compounds.
    DOI:
    10.1016/s0040-4020(01)86562-5
  • 作为产物:
    描述:
    三氯乙酸 作用下, 以 乙醇二氯甲烷 为溶剂, 以86%的产率得到
    参考文献:
    名称:
    New regiospecific synthesis of branched tetra-, nona- & deca-RNA modelling the lariat formed in RNA splicing reactions
    摘要:
    Convergent syntheses of branched tetraribonucleotide 39, nonaribonucleotide 40 and decaribonucleotide 41, modelling the lariat of pre-mRNA processing reaction, are reported. The first key step in the present strategy involves the condensation of the phosphodiester blocks 1, 5 or 15 with the 3',5'-dihydroxy-6-N-benzoyl-2'-O-pixyl(9-phenylxanthen-9-yl)adenosine 29 to give 30a (65%), 31a (63%) or 32a (70%). Chemospecific phosphorylation at 3'-OH of these intermediates afforded the intermediates 30b (92%), 31b (83%) or 32b (80%) which were treated with mild acid to achieve a regiospecific removal of the 2'-O-pixyl group to give compounds 30c (74%), 31c (86%) or 32c (85%). The second key step involved the introduction of biscyanoethylphosphotriester moiety to the 2'-OH of the branch-point adenosine in 30c, 31c or 32c in one single step using (biscyanoethoxy)-(diisopropylamino)phosphine to give the crucial branch-point building blocks 30d (46%), 31d (64%) or 32d (62%) with two dissimilar vicinal phosphates at 2'- and 3'- of the branch-point. These blocks were then converted to the fully protected intermediates 33a (59%) [30d+28 --> 33a], 34a (69%) [31d+19 --> 34a] and 35a (56%) [32d+19 --> 35a], and were subsequently treated with a bulky tertiary amine to give the branch-point 2'-cyanoethylphosphodiester blocks 33b (64%), 34b (67%) and 35b (68%). These were then condensed in the usual way with the appropriate 5'-hydroxy block (27 or 25) to give the fully protected branched oligomers 36 (69%) [33b+27 --> 36], 37 (67%) [34b+25 --> 37] and 38 (63%) [35b+25 --> 38]. These oligomers were then deprotected in the usual manner to give the final branched oligoribonucleotides 39, 40 and 41 in 62%, 21% and 21% yields respectively. Detailed 500 MHz H-1-NMR and 202.4 MHz P-31-NMR studies on 39, 40 and 41 have unequivocally established their purities. Detailed spectroscopic studies such as COSY, HOHAHA & NOESY have also clearly established the structural integrity of the synthetic target compounds.
    DOI:
    10.1016/s0040-4020(01)86562-5
点击查看最新优质反应信息

同类化合物

腺苷-3’-磷酸 胸苷酰-(3'-5')-胸苷氰基乙基磷酰三酯 胸腺嘧啶脱氧核苷3-单磷酸铵盐水合物 胞啶-3'-单磷酸二钠盐 环(腺苷酰(3'-5')尿苷单磷酸酯) 尿苷酸 尿苷溴乙酰甲醇5'-二磷酸酯 尿苷氯乙酰甲醇5'-二磷酸酯 丁二酸,甲基-,1-(苯基甲基)酯,(2R)-(9CI) [(2R,3S,4R,5R)-5-(6-氨基嘌呤-9-基)-4-羟基-2-(羟基甲基)四氢呋喃-3-基]苯基磷酸氢酯 [(2R,3S,4R,5R)-5-(2-氨基-6-氧代-3H-嘌呤-9-基)-2-[(2-甲酰基苯氧基)甲基]-4-羟基四氢呋喃-3-基]磷酸二氢酯 N-苯甲酰基-2'-脱氧-3'-胞苷酸2-氯苯基2-氰基乙基酯 8-[(E)-苄亚基氨基]-2'-脱氧腺苷3'-(磷酸二氢酯) 5-甲基-2'-脱氧胞苷-3'-磷酸 3'-(二氢磷酸)鸟嘌呤核苷 3'-(1-丁基磷酰)腺苷 2ˊ-脱氧胞苷-3ˊ-一磷酸 2-脱氧腺苷-3-单磷酸酯*铵 2'-脱氧鸟苷 3'-(磷酸二氢酯) 2'-脱氧腺苷酰-(3'-5')-2'-脱氧腺苷酰-(3'-5)-2'-脱氧腺苷 2'-脱氧-3'-胞苷酸二钠盐 2' -脱氧3' -磷酸游离酸 [3']thymidylic acid mono-[4-(2-iodo-acetylamino)-phenyl] ester 5-Fluor-1-β-D-arabinofuranosylcytosin-3'-phosphat [3']thymidylic acid mono-[4-(2-bromo-acetylamino)-phenyl] ester O2'-Methylguanosin-3'-phosphorsaeure uridine-3'-(2-cyanoethyl)phosphate [3']thymidylic acid mono-[4-(2-chloro-acetylamino)-phenyl] ester (1R)-1-(6-amino-purin-9-yl)-O3-phosphono-1,5-anhydro-D-glucitol Thymidin-3'-(2,4-dinitrophenyl)phosphat N4-Dimethylamino-methylen-2',5'-bis-O-(1-ethoxy-ethyl)-cytidin-3'-phosphat (2R)-3-((hydroxy(((2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)oxy)phosphoryl)oxy)propane-1,2-diyl dioleate 3-Methyl-uridin-3'-phosphat 2'-O-(tert-butyldimethylsilyl)inosine 3'-(allyl 2-cyanoethylphosphate) 2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-(2-chlorophenoxy)phosphoryl-2'-O-(2-tetrahydrofuranyl)-N4-(4-anisoyl)cytidine-3'-[O-(2-cyanoethyl)(2-chlorophenyl)phosphate] Phosphoric acid mono-[(2S,5R)-5-(2,4-diamino-pyrrolo[2,3-d]pyrimidin-7-yl)-2,5-dihydro-furan-2-ylmethyl] ester; compound with triethyl-amine 9-β.D-Glucopyranosyl-adenin-4'-phosphat 4-Oxo-pentanoic acid (2R,3S,5R)-3-[(2-chloro-phenoxy)-hydroxy-phosphoryloxy]-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester N(4),O(2')-Dibenzoyl-cytidin-3'-phosphat cis-((5-((4-amino-2-oxopyrimidin-1(2H)-yl)methyl)-1,3-oxathiolan-2-yl)methyl) (2R,3S,5R)-2-(hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl hydrogen phosphate 1,20-(icosanedioxy)bis-(3'-phosphatidyl-2'-deoxythymidine) 4-N-benzoyl-5'-O-[di(2-cyanoethyloxy)phosphoryl]-2'-deoxycytidylyl-{3'-OP-(2-cyanoethyl)->5'}-6-N-benzoyl-2',3'-di-O-(tert-butyldimethylsilyl)adenosine [3']uridylic acid mono-[1-(5,6-bis-ethoxycarbonylamino-pyrimidin-4-ylamino)-β-D-1-deoxy-ribofuranos-5-yl] ester 1-β-D-Arabinofuranosylcytidin-3'-phosphat OH[AA]AZMB